Featured Research

from universities, journals, and other organizations

Duke Study: Cold Needed To Preserve Livers For Transplant Also Can Kill Certain Cells

Date:
January 4, 2000
Source:
Duke University Medical Center
Summary:
A team of Duke University Medical Center researchers has figured out why donated livers can suffer a mysterious injury that damages their ability to perform well once transplanted. They found out that the cold temperature needed to preserve one set of specialized cells during the time the organ is out of a body is actually producing a chain reaction that ultimately results in the death of a different group of liver cells.

DURHAM, N.C. - A team of Duke University Medical Center researchers has figured out why donated livers can suffer a mysterious injury that damages their ability to perform well once transplanted.

They found out that the cold temperature needed to preserve one set of specialized cells during the time the organ is out of a body is actually producing a chain reaction that ultimately results in the death of a different group of liver cells.

While the findings point to a possible drug to block this process, the study suggests that liver transplant patients should not receive platelet transfusions before their procedures, as some centers routinely do.

The cells in question are called sinusoidal endothelial cells, highly specialized cells that appear only in the liver and which line the tiny blood vessels that form a vast network throughout the organ. Researchers had known that many of these cells become injured or die after the liver is re-attached to its new blood supply in the transplant recipient, but they didn't know the source of this "reperfusion" injury, which can impair liver function.

Immediately after removal from donors, livers are immersed in a special cold solution to preserve the function of hepatocytes, cells who have complex functions, producing as many as 5,000 different proteins. However, the low temperature (1 degree C) required to effectively preserve hepatocytes can also cause the sinusoidal cells -- which act as a detoxifying filter between the blood and hepatocytes -- to become deformed.

Using a unique system in which blood is circulated through a living and functioning liver outside a rat's body, the Duke researchers found that the cells died from a process known as apoptosis, or programmed cell death, and that the blood platelets initiated the apoptosis process.

"Our model showed that the longer the blood circulated through the reperfused liver, the more platelets stuck to the sinusoidal cells," said Dr. Pierre-Alain Clavien, lead researcher and chief transplant surgeon at Duke. "Further analysis of the cells showed that platelets adhered to the sinusoidal cells to trigger apoptosis.

"While we know that platelets are involved in clotting problems in transplants, this study demonstrates another role for platelets in causing problems in transplanted livers," he added.

The results of the study were published Thursday (Dec. 30) in the January issue of the journal Gastroenterology. The first author of the paper is Dr. David Sindram, also of Duke.

For transplant surgeons, the injury and death of the sinusoidal cells is the most important reason for graft failure after transplantation and one of the main challenges to be solved. In this regard, the surgeons face somewhat of a paradox, according to the Clavien.

"On one hand, we must keep the liver cold, which lowers the metabolic rate of the hepatocytes and preserves their function, but now we know that there is something about the period of cold preservation that makes the sinusoidal cells more susceptible to injury," Clavien said. "The cells do not die until they come into contact with blood and oxygen, and then they die very rapidly."

While the researchers do not know for sure what it is about the adhesion of platelets on sinusoidal cells that causes their death, the studies do point to a possible target for therapeutic intervention.

"When we added a sugar that inhibits platelet adhesion to our liver perfusion system, we found a significant reduction in the number of platelets sticking to the sinusoidal cells," Clavien said. "In these particular livers, there was also a corresponding significant reduction in the number of cells undergoing apoptosis."

This suggests that there may be a drug or substance that can be added to the solution used to preserve human livers that would keep platelets from adhering to sinusoidal cells, Clavien said. Aspirin, for example, inhibits platelet aggregation, but because of its blood-thinning properties, it would not be appropriate for someone undergoing a transplant.

While a possible drug may come in the future, Clavien said these findings should cause some centers to rethink their liver transplant protocols.

"Since the liver transplant procedure can involve a lot of blood loss, some centers give their patients platelets before surgery to offset potential losses," Clavien said. "Our data would suggest that this might not be appropriate."

While human livers remain viable outside the body in cold solution for up to 30 hours, liver surgeons know the sooner they can transplant the organ into the recipient, the less injury the organ sustains.

Clavien's group is pursuing what signals the platelets are sending to the sinusoidal cells to get them to commit suicide, as well as the possible role of immune system cells in the blood and the sinusoidal cell apoptosis.

The research was supported by a grant from the National Institutes of Health and from the Duke University department of surgery.

Joining Clavien and Sindram in the study were Duke researchers Dr. Robert Porte, Dr. Maureane Hoffman and Dr. Rex Bentley. Sindram is a research fellow in Clavien's lab and is supported by the Leiden (Netherlands) University Medical Center, the Netherlands Digestive Disease Foundation and the European Society for Organ Transplantation.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "Duke Study: Cold Needed To Preserve Livers For Transplant Also Can Kill Certain Cells." ScienceDaily. ScienceDaily, 4 January 2000. <www.sciencedaily.com/releases/2000/01/000104064827.htm>.
Duke University Medical Center. (2000, January 4). Duke Study: Cold Needed To Preserve Livers For Transplant Also Can Kill Certain Cells. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2000/01/000104064827.htm
Duke University Medical Center. "Duke Study: Cold Needed To Preserve Livers For Transplant Also Can Kill Certain Cells." ScienceDaily. www.sciencedaily.com/releases/2000/01/000104064827.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins